Glaukos Corp (GKOS) was Initiated by Cantor Fitzgerald to “Buy” and the brokerage firm has set the Price Target at $35. Cantor Fitzgerald advised their investors in a research report released on Jun 3, 2016.
Many Wall Street Analysts have commented on Glaukos Corp. Glaukos Corp was Initiated by Stifel to “Hold” on Apr 8, 2016.
On the company’s financial health, Glaukos Corp reported $0.03 EPS for the quarter, beating the analyst consensus estimate by $ 0.18 according to the earnings call on May 3, 2016. Analyst had a consensus of $-0.15. The company had revenue of $23.10 million for the quarter, compared to analysts expectations of $18.82 million. The company’s revenue was up 57.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.40 EPS.
Glaukos Corp closed down -0.03 points or -0.12% at $24.32 with 4,24,499 shares getting traded on Wednesday. Post opening the session at $24, the shares hit an intraday low of $23.47 and an intraday high of $24.35 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on May 26, 2016, Thomas William Burns (Chief Executive Officer) sold 300 shares at $25.00 per share price. According to the SEC, on May 5, 2016, Richard L Harrison (Treasurer, CFO & Secretary) sold 30,000 shares at $23.60 per share price. On May 5, 2016, Chris M. Calcaterra (Chief Commercial Officer) sold 74,536 shares at $23.45 per share price, according to the Form-4 filing with the securities and exchange commission.
Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company is engaged in the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent an MIGS device measuring one millimeter long and 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a small corneal incision. Glaukos is also engaged in developing a portfolio of micro-scale injectable therapies including three pipeline products namely the iStent Inject the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.